prexasertib prexasertib prexasertib (ly2606368) is a small molecule checkpoint kinase inhibitor, mainly active against chek1, with minor activity against chek2. this causes induction of dna double-strand breaks resulting in apoptosis. it was developed by eli lilly but the company announced in 2019 it was dropping prexasertib from active development, although clinical trials continue. research continues into the efficacy of prexasertib in treatment of acute myeloid leukemia, myelodysplastic syndrome, rhabdomyosarcoma, and medulloblastoma. prexasertibclinical datapregnancycategory iv atc codenoneidentifiers iupac name 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1h-pyrazol-3-yl)amino)-2-pyrazinecarbonitrile cas number1234015-52-1 ychemspider32738771unii820nh671e6keggd11206chemical and physical dataformulac18h19n7o2molar mass365.397 g·mol−13d model (jsmol)interactive image smiles c1=c(c(=c(c=c1)oc)c1=cc(=nn1)nc1=nc=c(n=c1)c#n)occcn inchi inchi=1s/c18h19n7o2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11h,3,6-7,19h2,1h3,(h2,22,23,24,25)key:dotgpnhgtyjdep-uhfffaoysa-n